1 / 26

Prescribing for Adolescents

Prescribing for Adolescents. Significant Psychosis**** Hyperactivity OCD Depression**** Tourettes/Tics Rare or not at all MR Autism Conduct Disorder Eating Disorders Sleep Disorder Anxiety Disorder Enuresis.

jana
Download Presentation

Prescribing for Adolescents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Prescribing for Adolescents

  2. Significant Psychosis**** Hyperactivity OCD Depression**** Tourettes/Tics Rare or not at all MR Autism Conduct Disorder Eating Disorders Sleep Disorder Anxiety Disorder Enuresis Scope – when is psychotropic drug treatment significant for children and adolescents?

  3. Key issues in Adolescence for Mental Health Services • Developmental issues • Physical development : puberty • Thinking and reasoning • Self and identity • Relations with family : transition & autonomy • Sexuality • Friendship and peer groups • Education, training and work • Anti-social and offending behaviour • Stress, coping and adjustment • Culture and ethnicity

  4. Limits on Child & Adolescent Psychopharmacolgy • Limited evidence base • Few RCTs • Reliance on downward extrapolation from adult studies • Developmental and pharmacodynamic differences child/adult • Off-label prescribing [USA 80%, Jensen 1999]

  5. Strategy for optimal psychopharmacological treatment of adolescents [The Big 8] • Clear psychiatric diagnosis • Identification and measurement of those features that are the target of treatment • Treatment “contract” with the patient (and when appropriate, the family] • Good knowledge about various treatment options and their relative risks and benefits • Factors that can influence treatment: • psychological, family, social, and economic • Useful methodology for determining efficacy and optimization of treatment • A constructively critical attitude about models of patho-etiology and how they relate to treatment. • Knowledge of and proficiency in a model of therapeutics that can allow for the implementation and integration of various useful treatments

  6. The school or work and social environment • Academic/work history • Peer relationships • Self-management/independent living skills • Contact school/college [with consent] • Reports etc

  7. Specific child & adolescent issues • Consent and capacity • MHA 1983 & Children Act 1989 • Gillick competence • Refusal of treatment by competent child • Child protection • Duty to protect • Violence and sexual aggression :in-patient units

  8. Baseline Assessment: General Issues • Patient and his or her symptoms • Psychiatric history • Mental State Examination • Measure specific symptoms that are focus of treatment • Medical Assessment including baseline assessment of symptoms which may later feature as adverse side effects

  9. The patient’s family or living unit • Family roles • Family psychiatric history • Response to previous treatments • Value systems and attitude to mental health issues and medication

  10. Practice points on family interviewing • Younger adolescents best seen with parents, then alone • Older adolescents need the choice • Depressed/anxious parents over-report child behaviour • Parents are less aware of mood states in their children • Crisis management/emergencies may require serial interviews and/or telephone contacts

  11. Adolescent onset schizophrenia (13-19 years of age) • 50 times less often before age 15 years than after it (Beitchrnan, 1985). • Average of first onset [EPPIC] 19 years • Insidious onsets more common • Long term Social outcomes are still very poor [Hollis 2000]

  12. Atypical Antipsychotics • Risperidone, Olanzepine, Quetiapine, Clozapine, Amisulpiride, • Standard antipsychotic choice for children & adolescents (70-80%o) • very limited evidence-base in younger patients (1 RCT:Kumra et al 1996) • possible increased efficacy against negative symptoms, cognitive impairment • Variable profile of side effects, reduced EPSE

  13. Side-Effects of Antipsychotics Can be more severe in children/ adolescents than adults and include: • Dystonias/ EPSE/TD • Increased appetite and weight gain • Type II diabetes & lipid changes • Blood dyscrasias (neutropenia/ agranulocytosis) • Cardiac arrhythmias, inc. QTc interval • elevated prolactin -> reduced estrogen,osteoporosis • Seizures

  14. Side Effect Profiles

  15. EPSE BY AGE

  16. Weight Gain in Adolescents Olanzepine vs. Risperidone vs. Haloperidol Mean age 17 years mean dosage: Olanzepine 12.7mg. Risperidone 3.2mg. Haloperidol 7.6mg

  17. Drug Initiation • Start Low, Go Slow • Risperidone 0.5mgs • Olanzapine 2.5mgs nocte • Clozapine 12.5mgs [50mgs/2days] • Increase every 3 to 5 days • Most side-effects occur early (first 4-6 weeks) • Add benzodiazepine (e.g lorazepam 1-2 mg, diazepam 2-5mgs, Clonazepam 0.5-2mgs) for arousal/ agitation • Severe violence/agitation may need RT protocol

  18. Atypicals: Target Dose Ranges mgs • Risperidone 2-6 • Olanzepine 2.5-20 • Quetiapine 150-600/750 b.d. • Amisulpiride 400-1200 • Clozapine 300-600 Clozapine plasma level >350ng/ml (0.35mg/L))

  19. Switch to Clozapine • Review diagnosis and treatment compliance • Consider lithium if marked affective component • Consider Shot antipsychotic if compliance poor • Switch to clozapine: titrate to optimal dose. • Control for plasma levels and side effects, Continue for 3 – 6 months not effective or not tolerated

  20. If Clozapine does not work • Review diagnosis and treatment compliance; withdraw all ineffective medication; give previous most effective drug lowest effective dose; or • Consider another atypical or depot antipsychotic; • re-consider cognitive behavioural intervention

  21. summary • Schizophrenia in children and adolescents requires early detection and intervention. • atypicals are first line Tx • side Effect profiles mainly determine choice • share information and decisions with patient and family • interpretation of [NICE] time scales is not clear for >18 • is early use of Clozapine justified?

  22. Depression (1975), Marion Patrick (1940-1993) ‘A child endures or enjoys overwhelming misery or overwhelming happiness because he isolates the moment and does not connect it with the future or the past. In my work I try to convey this isolation’.

  23. Antidepressants for <l8’sPosition up to June 2003 • TCA’s: in RCT’s, lack efficacy; risky side-effects, e.g. cardiac • MAOI’s: no RCTs; high toxicity • SSRIs: Until 2003, considered relatively safe; • Fluoxetine and Paroxetine efficacious in RCT’s; many open label trials; ‘TREATMENT OF CHOICE’ • Nefazodone (NASSA), Venlafaxine (SNRI), some studies (inconclusive)

  24. Antidepressants in ~18’s – current position :Jan. 2004 Licensed use • US: Fluoxetine for OCD [>7yrs+ ] and depression [>8yrs] • Sertraline for OCD [>6yrs) • Paroxetine and Venlafaxine contraindicated: new data show unfavourable balance of risks [esp. re suicidality] vs benefits. • Fluvoxamine may be used for OCD • Expert Working Group Looking urgently at wider safety issues re SSRl’s in paediatric population

  25. CBT for depressed children and adolescents – does it work? • NOT for severely depressed adolescents [Harrington 1998] • Treatment of choice for mild/moderate depression, high rates of recurrence. • IPT - promising, only one RCT

  26. Prognosis – the transition to adulthood • Most will recover from their depressive Episode • However, high rate of recurrence Predicted by severe presentation and Absence of conduct disorder • Rapid cycling mood overlaps with Emotionally Unstabel PD • Dysthymia often confused with depressive Episodes • Small number develop Bipolar Disorder Small number go on to kill themselves

More Related